https://9690c.iqanda-cme.com/1 2019-06-06T22:52:09+0000 weekly 1 https://9690c.iqanda-cme.com/submit-a-question 2019-05-08T18:12:53+0000 weekly 0.8 https://9690c.iqanda-cme.com/lipid-medicine-and-atherosclerosis-prevention 2019-09-07T01:28:17+0000 weekly 0.8 https://9690c.iqanda-cme.com/about-iqanda-lipid-atherosclerosis 2019-03-29T23:03:17+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-a-lipid-specialist-s-perspective-do-the-results-from-the-odyssey-outcomes-trial-suggest-the-need-to-be-more-focused-on-achieving-absolute-target-levels-of-ldl-c-or-relative-percentage-reductions-in-ldl-c-levels 2019-04-01T20:11:30+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/do-you-see-safety-signals-associated-with-ultra-aggressive-ldl-c-lowering-and-what-is-the-role-of-pad-as-a-risk-factor-guiding-ldl-c-reduction 2019-04-01T20:11:25+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-the-setting-of-secondary-prevention-for-patients-with-diabetes-the-role-of-ldl-c-has-special-significance-how-do-you-view-the-importance-for-the-of-pcsk9-inhibitors-therefore-specifically-for-reducing-residual-cv-risk-in-the-t2d-popul 2019-04-01T20:11:23+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-which-of-your-patients-with-fh-do-you-feel-psck9-inhibitors-will-become-foundational-agents-in-conjunction-with-statins-when-tolerated 2019-04-08T04:43:10+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/why-are-patients-who-should-clearly-be-on-a-pcsk9-inhibitor-not-being-treated-in-the-primary-cardiology-setting-but-rather-seeking-and-obtaining-this-treatment-in-the-lipid-clinic-environment 2019-04-01T20:34:53+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/as-a-leading-authority-in-ldl-c-mediated-cv-risk-reduction-can-you-provide-us-with-your-perspective-on-the-evidence-for-pcsk9-inhibitors-as-a-foundational-approach-for-managing-a-broad-spectrum-of-patients-with-high-risk-coronary-heart-d 2019-04-01T20:38:29+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-and-atherosclerosis-specialist-assuming-that-the-barriers-to-pcsk9-inhibitors-are-reduced-which-patients-at-risk-for-or-with-confirmed-ascvd-represent-the-best-risk-directed-candidates-for-ldl-c-lowering 2019-04-08T04:33:26+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-a-lipid-specialist-perspective-how-do-you-navigate-the-risk-territory-of-ldl-c-levels-70-mg/dl-with-pcsk9-inhibitors-and-in-which-patient-subgroups-do-these-agents-offer-unique-outcome-related-benefits 2019-04-08T04:32:38+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/ic-and-lipid-specialists-are-challenged-to-maximize-cv-risk-reduction-in-high-risk-populations-how-should-they-approach-the-70-mg/dl-ldl-c-target-identified-in-the-aha-guidelines-and-when-is-the-30-mg/dl-70-mg/dl-even-more-desirable 2019-04-01T20:34:08+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/professor-bhatt-you-presented-the-pharmacoeconomic-in-trial-analysis-for-alirocumab-based-on-the-odyssey-outcomes-trial-can-you-discuss-the-clinical-implications-of-your-analysis-and-how-reduced-costs-for-alirocumab-will-affect-ic-practi 2019-04-16T18:13:46+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-your-lipid-practice-which-patients-with-ascvd-do-you-prioritize-for-pcsk9-mediated-lowering-of-ldl-c-based-on-odyssey-outcomes-what-do-we-know-about-the-subgroup-of-post-acs-patients-who-benefited-most-from-alirocumab 2019-04-08T04:43:53+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/where-did-the-70-mg/dl-ldl-c-target-goal-come-from-why-wasn-t-it-set-lower-in-the-guidelines-from-the-outset-for-patients-with-acs 2019-04-01T20:13:51+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-should-the-threshold-of-70-mg/dl-identified-in-the-aha-guidelines-mean-to-the-medical-or-preventive-cardiologist-in-his/her-aspiration-to-optimize-cv-risk-reduction-in-high-risk-patients-with-a-history-of-acs-or-related-high-risk-fe 2019-04-01T20:11:27+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/which-patients-in-your-view-are-not-candidates-for-pcsk9-inhibition 2019-04-08T04:47:38+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/to-what-degree-have-you-observed-statin-intolerance-or-resistance-in-patients-with-high-risk-cad-what-protocol-do-you-employ-to-mitigate-and/or-manage-statin-intolerance-where-does-the-pcsk9-inhibitor-fit-into-your-sequencing-strategy 2019-04-01T20:14:27+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-is-your-experience-deploying-pcsk9-inhibitors-in-the-clinic-and-what-are-the-most-reliable-and-actionable-triggers-for-deploying-this-program-for-cv-risk-reduction-and-predictably-achieving-reimbursement-and-payor-support-for-this-t 2019-04-01T20:38:19+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/although-the-aha-guidelines-identify-a-70-mg/dl-threshold-target-for-patients-at-high-risk-for-recurrent-acs-do-you-believe-this-is-merely-a-starting-point-identifying-a-minimal-level-of-ldl-c-goal-attainment 2019-04-01T20:11:39+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-patients-requiring-down-titration-of-their-statins-due-to-muscle-discomfort/pain-what-is-the-trigger-point-for-moving-beyond-statins-to-consider-pcsk9-inhibitors 2019-04-08T04:41:38+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-should-the-lipid-and-atherosclerosis-disease-specialist-interpret-the-esc-and-aha-guideline-threshold-of-70-mg/dl-ldl-c-level-and-determine-whether-even-lower-levels-are-even-better-to-mitigate-residual-cv-risk 2019-04-08T04:38:23+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/as-an-interventional-cardiologist-in-the-uk-what-do-the-results-from-the-odyssey-outcomes-trial-and-price-reductions-mean-to-the-clinician-at-the-front-lines-of-cardiology-care-as-far-as-access-to-and-triggers-for-deploying-a-pcsk9-inhib 2019-04-01T20:14:22+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/as-the-director-of-the-center-for-cardiovascular-disease-prevention-what-patient-types-on-the-risk-landscape-of-ascvd-do-you-believe-deserve-special-attention-because-they-are-likely-to-be-eligible-candidates-for-pcsk9-mediated-ldl-c-red 2019-04-01T20:38:30+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/can-you-paint-the-profile-of-the-post-acs-patient-with-t2d-in-whom-the-aggregate-cv-risk-exceeds-a-threshold-that-supports-a-strategy-of-pcsk9-mediated-ldl-c-reduction-in-order-to-achieve-levels-of-less-than-70-mg/dl-or-even-less-than-50 2019-04-01T20:11:21+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-should-the-fact-that-cv-risk-is-not-binary-but-progressive-influence-the-decision-to-use-a-pcsk9-inhibitor 2019-04-01T20:14:23+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-specialist-especially-in-light-of-the-associated-all-cause-mortality-reductions-reported-in-odyssey-outcomes-how-should-the-clinician-be-thinking-about-pcsk9-inhibitors-as-a-tool-in-their-day-to-day-practi 2019-04-08T04:35:04+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/although-70-mg/dl-is-the-target-threshold-identified-by-both-esc-and-aha-should-the-interventionalist-in-a-patient-who-has-just-undergone-a-pci-and-has-an-ldl-c-of-69-mg/dl-be-considered-adequately-cv-risk-mitigated 2019-04-01T20:14:21+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/when-is-70-mg/dl-not-good-enough-is-this-a-threshold-what-clinical-factors-suggest-lower-targets-are-better-what-is-happening-at-the-vascular-biology-level 2019-04-01T20:34:55+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-a-lipid-medicine-specialist-s-perspective-what-would-your-approach-be-to-a-post-acs-patient-with-two-stents-and-triple-vessel-disease-whose-ldl-c-level-is-70-mg/dl 2019-04-08T04:31:51+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-are-your-2019-esc/eas-guidelines-going-to-be-influenced-by-recent-rcts-including-odyssey-outcomes-and-fourier 2019-04-01T20:13:59+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/can-you-describe-the-actual-clinical-phenotypes-actual-patients-referred-to-you-by-interventional-or-medical-cardiologists-in-which-pcsk9-inhibition-would-represent-a-foundational-approach-to-reduction-of-residual-cv-risk-burden 2019-04-01T20:35:04+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-vigorous-should-we-be-in-trying-to-lower-ldl-c-in-patients-who-have-statin-intolerance-what-is-the-role-of-combined-so-called-backbone-statin-treatment-plus-pcsk9-inhibitor-therapy 2019-04-08T04:39:58+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-does-the-pharmacoeconomic-landscape-currently-look-like-for-pcsk9-inhibition-especially-in-light-of-the-recent-price-reductions-for-alirocumab-and-evolocumab 2019-03-27T20:01:47+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/considering-that-younger-persons-are-vulnerable-to-carrying-a-lifelong-atherosclerosis-burden-when-their-ldl-c-levels-are-elevated-how-to-do-approach-them-management-wise 2019-04-08T04:29:22+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/you-have-identified-the-challenges-of-accessing-pcsk9-inhibitors-for-patients-whose-cv-risk-is-genetic-vs-those-whose-clinical-course-is-characterized-by-progressive-vascular-events-how-do-you-approach-each-subset-with-respect-to-ldl-c-m 2019-04-01T20:38:32+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-do-you-approach-younger-patients-with-known-advanced-subclinical-atherosclerosis 2019-04-01T20:38:26+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/given-the-results-of-odyssey-fourier-and-others-as-a-lipid/atherosclerosis-specialist-what-is-your-take-home-about-what-the-appetite-should-be-for-using-pcsk9-inhibitors-to-lower-ldl-c-levels-beyond-esc-and-aha-recommended-thresholds-of- 2019-04-08T04:36:03+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/as-a-lead-investigator-for-both-fh-and-ascvd-focused-trials-evaluating-pcsk9-inhibitors-what-is-your-interpretation-of-the-data-confirming-regimen-adherence-and-compliance-with-these-injectable-agents 2019-04-01T20:34:01+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-specific-ldl-c-related-endpoints-are-likely-to-undergo-review-and-revisions-based-on-the-publication-of-two-pcsk9-related-trials-odyssey-outcomes-and-fourier 2019-04-08T04:46:48+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-change-in-practice-based-on-the-all-cause-mortality-reduction-reported-in-odyssey-outcomes-do-you-believe-is-warranted-especially-as-these-results-might-impact-the-ldl-c-level-that-should-be-targeted-and-the-duration-of-therapy 2019-04-08T04:46:02+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-the-lipid-clinic-setting-in-patients-you-have-treated-with-pcsk9-inhibitors-what-are-you-finding-as-far-as-regimen-adherence-toleration-and-patient-engagement/satisfaction-with-these-injectable-strategies 2019-04-08T04:42:24+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-other-markers-besides-ldl-c-levels-do-you-believe-we-should-consider-to-refine-cv-risk-stratification 2019-04-01T20:34:11+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/given-that-odyssey-outcomes-has-shown-not-only-reduction-in-cv-events-but-also-a-reduction-in-associated-all-cause-mortality-what-is-the-role-of-pcsk9-inhibitors-in-diabetes-patients-with-a-prior-acs-event 2019-04-01T20:11:26+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-should-the-2018-aha-guidelines-for-ldl-c-that-specify-target-levels-for-high-risk-patients-impact-our-approach-to-selecting-therapies-including-pcsk9-inhibitors-that-have-the-potential-to-lower-ldl-c-to-levels-far-lower-than-those-re 2019-03-27T21:54:53+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-a-lipid-medicine-and-preventive-cardiovascular-perspective-how-do-you-triage-the-diabetic-patient-with-acs-into-a-pcsk9-based-treatment-strategy-for-ldl-c-reduction 2019-03-27T19:51:13+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-do-you-identify-progressing-patients-with-high-cv-risk-in-whom-pcsk9-therapy-represents-a-game-changing-strategy 2019-04-01T20:34:05+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-a-patient-centric-clinical-profile-perspective-which-high-risk-burden-patient-populations-do-you-as-an-atherosclerosis-specialist-single-out-for-pcsk9-mediated-ldl-c-reduction 2019-04-01T20:11:38+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-a-lipid-medicine-and-atherosclerosis-expert-s-perspective-when-you-look-at-the-odyssey-outcomes-and-fourier-trials-what-consistent-or-comparative-message-do-you-take-from-these-investigations-into-the-safety-and-efficacy-of-pcsk9-in 2019-04-08T04:30:18+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-should-the-lipid-specialist-approach-the-individual-with-diabetes-who-doesn-t-yet-have-ascvd 2019-04-08T04:39:17+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-the-view-of-an-interventional-cardiologist-and-a-lipid-medicine/atherosclerosis-specialist-can-you-discuss-what-ldl-c-thresholds-vs-clinical-burden/clinical-history-thresholds-are-important-for-patient-selection-for-pcsk9-based-risk 2019-04-01T20:34:03+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/now-with-the-publication-of-odyssey-outcomes-which-demonstrated-an-associated-all-cause-mortality-reduction-benefit-how-do-you-view-the-foundational-role-of-pcsk9-inhibitors-in-the-cv-risk-treatment-plan-for-high-risk-patient-populations 2019-04-08T04:44:31+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-light-of-the-effectiveness-and-safety-in-post-acs-patients-of-the-ultra-low-levels-of-ldl-c-achieved-in-the-odyssey-outcomes-and-fourier-trials-how-has-that-shaped-your-clinical-perspective-on-the-role-of-pcsk9-inhibitors-in-high-risk 2019-04-08T04:40:57+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/you-have-introduced-the-concept-of-progressive-atherosclerotic-burden-to-characterize-the-multiplicity-of-biologic-metabolic-and-clinical-markers-in-a-cv-risk-profile-how-do-you-apply-this-aggregated-risk-to-patient-selection-for-pcsk9-i 2019-04-01T20:11:32+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/do-you-use-different-ldl-c-levels-in-persons-with-diabetes-to-justify-initiation-of-pcsk9-inhibitors-is-the-presence-of-acs-required-or-symptomatic-ascvd-required-to-triage-them-into-pcsk9-based-treatment 2019-03-27T19:57:34+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-your-mind-as-a-director-of-a-lipid-clinic-and-preventive-cardiology-center-how-do-you-apply-the-results-of-the-odyssey-outcomes-and-other-trials-in-terms-of-the-lack-of-safety-signals-when-lowering-ldl-c-to-levels-50-mg/dl 2019-04-01T20:38:21+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/which-patient-subgroups-that-based-on-the-odyssey-outcomes-trial-could-benefit-significantly-from-a-pcsk9-inhibitor-in-your-observation-are-not-getting-treatment-consistently-enough-i-e-are-being-under-treated-with-these-agents 2019-04-01T20:14:36+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/in-the-type-2-diabetes-population-that-you-manage-in-your-what-percentage-of-patients-do-you-estimate-do-not-achieve-risk-appropriate-ldl-c-for-any-number-of-reasons-is-it-as-high-as-10-as-reported-in-by-some-diabetes-experts 2019-04-01T20:11:22+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/can-you-cite-specific-patient-types-where-you-are-strongly-inclined-to-use-a-pcsk9-inhibitor-because-achieving-both-significant-percentage-based-reductions-in-ldl-c-level-as-well-as-achieving-an-ldl-c-level-70mg/dl-are-of-critical-import 2019-04-08T04:28:21+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/which-patients-in-your-view-based-on-the-odyssey-outcomes-and-fourier-trials-do-you-want-to-drive-below-the-ldl-c-threshold-of-70-mg/dl-what-is-your-rationale-and-how-do-you-select-your-patients-and-achieve-your-targets-in-the-real-world 2019-04-01T20:38:22+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/with-the-results-of-odyssey-outcomes-and-the-more-attractive-pricing-for-pcsk9-inhibitors-how-do-you-now-see-the-landscape-for-this-therapy-especially-in-the-context-of-the-lipid-medicine/atherosclerosis-specialist-and-the-preventive-car 2019-04-01T20:11:36+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/based-on-odyssey-outcomes-for-which-biological/metabolic-risk-markers-do-you-feel-that-cardiologists-and-atherosclerosis-specialists-should-strive-to-achieve-ldl-c-levels-even-more-aggressive-than-those-identified-in-the-aha-guidelines 2019-04-01T20:38:31+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/given-the-new-guidelines-price-reductions-and-the-reduction-in-associated-all-cause-mortality-reported-with-alirocumab-in-odyssey-outcomes-which-patients-should-now-be-embraced-as-plausible-candidates-for-pcsk9-mediated-cv-risk-reduction 2019-04-01T20:38:24+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/given-what-we-know-about-the-safety-of-pcsk9-inhibitors-and-the-risk-of-recurrent-events-in-patients-who-have-experienced-an-acs 2019-04-08T04:36:50+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-medicine-specialist-how-do-the-results-of-the-now-published-odyssey-outcomes-trial-and-related-trials-help-you-select-patients-for-pcsk9-mediated-ldl-c-reduction-and-what-targets-do-you-advocate 2019-04-08T04:34:18+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/given-the-reduction-in-both-cv-outcomes-and-associated-all-cause-mortality-are-the-ldl-c-thresholds-currently-recommended-by-the-aha-and-esc-low-enough-and-what-are-the-implications-for-pcsk9-mediated-cv-risk-reduction 2019-04-01T20:11:29+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/a-confluence-of-events-has-reshaped-the-accessibility-evidence-basis-and-actionability-profile-for-pcsk9-inhibitors-as-an-atherosclerosis-specialist-how-have-these-developments-changed-the-equation-and-shaped-your-approach-to-cv-risk-red 2019-04-01T20:11:41+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/representing-the-landscapes-of-ic-and-atherosclerosis-prevention/lipid-management-how-do-you-identify-progressing-patients-with-high-cv-risk-in-whom-pcsk9-therapy-represents-a-game-changing-strategy 2019-03-27T21:53:43+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/should-lipidologists-consider-other-markers-such-as-apob-as-well-as-ldl-c-for-reducing-cv-risk-in-diabetes-and-hypertriglyceridemia 2019-04-01T20:13:54+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/how-have-recent-pcsk9-trials-affected-your-position-on-the-role-of-intensifying-ldl-c-reductions-to-new-target-levels-and-how-are-they-likely-to-affect-future-global/esc-2019-guidelines-for-ldl-mediated-cv-risk-reduction 2019-04-08T04:37:32+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/the-pcsk9-trials-have-confirmed-a-the-absence-of-a-j-point-curve-for-ldl-c-lowering-and-b-continuing-cv-risk-reduction-even-when-lowering-ldl-c-from-100-mg/dl-to-30-mg/dl-in-light-of-this-how-should-the-lipid-specialist-deploy-pcsk9-inhi 2019-04-01T20:11:33+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/what-are-the-specific-patient-types-that-you-manage-in-your-lipid-focused-practice-and-which-are-referred-to-you-for-potential-intervention-with-a-pcsk9-inhibitor-why-are-these-patients-being-referred-to-you-for-pcsk9-mediated-ldl-c-redu 2019-04-08T04:45:17+0000 weekly 0.8 https://9690c.iqanda-cme.com/videos/with-the-odyssey-outcomes-trial-s-favorable-pharmacoeconomic-analysis-now-established-and-a-reduction-in-all-cause-mortality-with-alirocumab-where-do-you-see-the-evidence-based-opportunities-for-these-agents-in-your-practice-setting 2019-04-01T20:11:35+0000 weekly 0.8 https://9690c.iqanda-cme.com/courses/iqanda-pcsk9-cardiovascular-medicine-intelligence-zone 2023-04-14T03:39:23+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/lipid-medicine-and-atherosclerosis-prevention 2019-03-28T01:05:47+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/applicability-and-cost-implications-for-pcsk9-inhibitors-based-on-the-odyssey-outcomes-trial 2019-03-28T01:07:06+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/infographic-nla-expert-panel-pcsk9-recommendations 2019-03-28T01:06:16+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/2016-esc/eas-guidelines-for-the-management-of-dyslipidaemias 2019-03-28T01:07:23+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/nla-expert-panel-pcsk9-recommendations 2019-03-28T01:06:30+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/fourier-further-cardiovascular-outcomes-research-with-pcsk9-inhibition-in-subjects-with-elevated-risk 2019-03-29T01:01:58+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/2018-aha/acc-guideline-on-the-management-of-blood-cholesterol 2019-03-28T01:07:39+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/pooled-analysis-of-10-odyssey-trials-comparing-reductions-in-atherogenic-lipids-and-major-cv-events 2019-03-28T01:06:44+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list 2019-03-30T00:37:17+0000 weekly 0.8 https://9690c.iqanda-cme.com/flexpaper/the-odyssey-outcomes-trial-topline-results-alirocumab-in-patients-after-acute-coronary-syndrome 2019-03-28T01:07:54+0000 weekly 0.8